Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978)

Overview

Journal J Med Chem

Publisher American Chemical Society

Specialty Chemistry

Date 2016 Dec 10

PMID 27933964

Citations 6

Authors

Chunkai Wang

Qingjie Zhao

Mireille Vargas

Jeremy O Jones

Karen L White

David M Shackleford

Gong Chen

Jessica Saunders

Alice C F Ng

Francis C K Chiu

Yuxiang Dong

Susan A Charman

Jennifer Keiser

Jonathan L Vennerstrom

Affiliations

Soon will be listed here.

Abstract

The aryl hydantoin 1 (Ro 13-3978) was identified in the early 1980s as a promising antischistosomal lead compound. However, this series of aryl hydantoins produced antiandrogenic side effects in the host, a not unexpected outcome given their close structural similarity to the antiandrogenic drug nilutamide. Building on the known SAR of this compound series, we now describe a number of analogs of 1 designed to maximize structural diversity guided by incorporation of substructures and functional groups known to diminish ligand-androgen receptor interactions. These analogs had calculated polar surface area (PSA), measured LogD, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of good ADME profiles. The principal SAR insight was that the hydantoin core of 1 is required for high antischistosomal activity. We identified several compounds with high antischistosomal efficacy that were less antiandrogenic than 1. These data provide direction for the ongoing optimization of antischistosomal hydantoins.

Citing Articles

Chiral Recognition of Hydantoin Derivatives Enabled by Tetraaza Macrocyclic Chiral Solvating Agents Using H NMR Spectroscopy.

Wen J, Feng L, Zhao H, Zheng L, Stavropoulos P, Ai L J Org Chem. 2022; 87(12):7934-7944.

PMID: 35675642 PMC: 9463821. DOI: 10.1021/acs.joc.2c00587.

Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?.

Dziwornu G, Attram H, Gachuhi S, Chibale K RSC Med Chem. 2021; 11(4):455-490.

PMID: 33479649 PMC: 7593896. DOI: 10.1039/d0md00062k.

Cu-catalyzed -3-Arylation of Hydantoins Using Diaryliodonium Salts.

Berntsen L, Nova A, Wragg D, Sandtorv A Org Lett. 2020; 22(7):2687-2691.

PMID: 32202123 PMC: 7309330. DOI: 10.1021/acs.orglett.0c00642.

SAR of a new antischistosomal urea carboxylic acid.

Wu J, Wang C, Haberli C, White K, Shackleford D, Chen G Bioorg Med Chem Lett. 2018; 28(23-24):3648-3651.

PMID: 30389288 PMC: 6301076. DOI: 10.1016/j.bmcl.2018.10.039.

Progress in antischistosomal N,N'-diaryl urea SAR.

Wu J, Wang C, Leas D, Vargas M, White K, Shackleford D Bioorg Med Chem Lett. 2018; 28(3):244-248.

PMID: 29317164 PMC: 6026081. DOI: 10.1016/j.bmcl.2017.12.064.

References

de Mendonca R, Escriva H, Bouton D, Laudet V, Pierce R . Hormones and nuclear receptors in schistosome development. Parasitol Today. 2000; 16(6):233-40. DOI: 10.1016/s0169-4758(00)01641-0. View

Jones J, Diamond M . A cellular conformation-based screen for androgen receptor inhibitors. ACS Chem Biol. 2008; 3(7):412-8. DOI: 10.1021/cb800054w. View

Keiser J, Utzinger J . Antimalarials in the treatment of schistosomiasis. Curr Pharm Des. 2012; 18(24):3531-8. View

Forget E, Felix H, NOTTEGHEM M, Leger N . [Efficacy of schistosomicide derivatives, appreciation with electronic microscopy experimental model (author's transl)]. Bull Soc Pathol Exot Filiales. 1982; 75(2):192-200. View

Wang C, Zhao Q, Min J, Muniyan S, Vargas M, Wang X . Antischistosomal versus antiandrogenic properties of aryl hydantoin Ro 13-3978. Am J Trop Med Hyg. 2014; 90(6):1156-8. PMC: 4047746. DOI: 10.4269/ajtmh.14-0029. View

Liu Y, Wu W, Liang Y, Jie Z, Wang H, Wang W . New uses for old drugs: the tale of artemisinin derivatives in the elimination of schistosomiasis japonica in China. Molecules. 2014; 19(9):15058-74. PMC: 6271675. DOI: 10.3390/molecules190915058. View

Melman S, Steinauer M, Cunningham C, Kubatko L, Mwangi I, Wynn N . Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni. PLoS Negl Trop Dis. 2009; 3(8):e504. PMC: 2721635. DOI: 10.1371/journal.pntd.0000504. View

Zhang X, Allan G, Sbriscia T, Linton O, Lundeen S, Sui Z . Synthesis and SAR of novel hydantoin derivatives as selective androgen receptor modulators. Bioorg Med Chem Lett. 2006; 16(22):5763-6. DOI: 10.1016/j.bmcl.2006.08.084. View

Cioli D, Pica-Mattoccia L, Basso A, Guidi A . Schistosomiasis control: praziquantel forever?. Mol Biochem Parasitol. 2014; 195(1):23-9. DOI: 10.1016/j.molbiopara.2014.06.002. View

10.

Hansen J, HAFLIGER O . Determination of the dissociation constant of a weak acid using a dissolution rate method. J Pharm Sci. 1983; 72(4):429-31. DOI: 10.1002/jps.2600720426. View

11.

Utzinger J, NGoran E, Caffrey C, Keiser J . From innovation to application: social-ecological context, diagnostics, drugs and integrated control of schistosomiasis. Acta Trop. 2010; 120 Suppl 1:S121-37. DOI: 10.1016/j.actatropica.2010.08.020. View

12.

Bolton E, So A, Chaivorapol C, Haqq C, Li H, Yamamoto K . Cell- and gene-specific regulation of primary target genes by the androgen receptor. Genes Dev. 2007; 21(16):2005-17. PMC: 1948856. DOI: 10.1101/gad.1564207. View

13.

Bevan C, Lloyd R . A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates. Anal Chem. 2000; 72(8):1781-7. DOI: 10.1021/ac9912247. View

14.

Panic G, Vargas M, Scandale I, Keiser J . Activity Profile of an FDA-Approved Compound Library against Schistosoma mansoni. PLoS Negl Trop Dis. 2015; 9(7):e0003962. PMC: 4521867. DOI: 10.1371/journal.pntd.0003962. View

15.

Olliaro P, Delgado-Romero P, Keiser J . The little we know about the pharmacokinetics and pharmacodynamics of praziquantel (racemate and R-enantiomer). J Antimicrob Chemother. 2014; 69(4):863-70. DOI: 10.1093/jac/dkt491. View

16.

Kasinathan R, Greenberg R . Pharmacology and potential physiological significance of schistosome multidrug resistance transporters. Exp Parasitol. 2011; 132(1):2-6. PMC: 3154572. DOI: 10.1016/j.exppara.2011.03.004. View

17.

Keiser J . In vitro and in vivo trematode models for chemotherapeutic studies. Parasitology. 2009; 137(3):589-603. DOI: 10.1017/S0031182009991739. View

18.

Keiser J, Manneck T, Vargas M . Interactions of mefloquine with praziquantel in the Schistosoma mansoni mouse model and in vitro. J Antimicrob Chemother. 2011; 66(8):1791-7. DOI: 10.1093/jac/dkr178. View

19.

Vinggaard A, Niemela J, Wedebye E, Jensen G . Screening of 397 chemicals and development of a quantitative structure--activity relationship model for androgen receptor antagonism. Chem Res Toxicol. 2008; 21(4):813-23. DOI: 10.1021/tx7002382. View

20.

Lombardo F, Shalaeva M, Tupper K, Gao F . ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds. J Med Chem. 2001; 44(15):2490-7. DOI: 10.1021/jm0100990. View